Pharmaceutical Preformulation and Formulation A

Practical Guide from Candidate Drug Selection to

Commercial Dosage Form Second Edition Drugs and the
Pharmaceutical Sciences 199 Mark Gibson 2025 pdf
download

Order now at ebookfinal.com

https://ebookfinal.com/download/pharmaceutical-preformulation-and-
formulation-a-practical-guide-from-candidate-drug-selection-to-
commercial-dosage-form-second-edition-drugs-and-the-pharmaceutical-
sciences-199-mark-gibson/

★★★★★
4.6 out of 5.0 (91 reviews )

PDF Instantly Ready

 Pharmaceutical Preformulation and Formulation A Practical
Guide from Candidate Drug Selection to Commercial Dosage
Form Second Edition Drugs and the Pharmaceutical Sciences
199 Mark Gibson Pdf Download

EBOOK

Available Formats

■ PDF eBook Study Guide Ebook

EXCLUSIVE 2025 ACADEMIC EDITION – LIMITED RELEASE

Available Instantly Access Library

Here are some recommended products for you. Click the link to
download, or explore more at ebookfinal

Drug Drug Interactions Second Edition Drugs and the

Pharmaceutical Sciences A. David Rodrigues

https://ebookfinal.com/download/drug-drug-interactions-second-edition-
drugs-and-the-pharmaceutical-sciences-a-david-rodrigues/

Clinical Drug Trials and Tribulations Second Edition Drugs

and the Pharmaceutical Sciences Cato

https://ebookfinal.com/download/clinical-drug-trials-and-tribulations-
second-edition-drugs-and-the-pharmaceutical-sciences-cato/

Drug Products for Clinical Trials Second Edition Drugs and

the Pharmaceutical Sciences Donald Monkhouse

https://ebookfinal.com/download/drug-products-for-clinical-trials-
second-edition-drugs-and-the-pharmaceutical-sciences-donald-monkhouse/

Pharmaceutical Inhalation Aerosol Technology Second

Edition Drugs and the Pharmaceutical Sciences Anthony J.
Hickey
https://ebookfinal.com/download/pharmaceutical-inhalation-aerosol-
technology-second-edition-drugs-and-the-pharmaceutical-sciences-
anthony-j-hickey/
Freeze Drying Lyophilization Of Pharmaceutical Biological
Products Third Edition Drugs and the Pharmaceutical
Sciences 206 Louis Rey
https://ebookfinal.com/download/freeze-drying-lyophilization-of-
pharmaceutical-biological-products-third-edition-drugs-and-the-
pharmaceutical-sciences-206-louis-rey/

Handbook of Pharmaceutical Granulation Technology Third

Edition Volume 198 Drugs and the Pharmaceutical Sciences
Dilip M. Parikh
https://ebookfinal.com/download/handbook-of-pharmaceutical-
granulation-technology-third-edition-volume-198-drugs-and-the-
pharmaceutical-sciences-dilip-m-parikh/

Proteins and Peptides Pharmacokinetic Pharmacodynamic and

Metabolic Outcomes Volume 202 Drugs and the Pharmaceutical
Sciences 1st Edition Randall J. Mrsny
https://ebookfinal.com/download/proteins-and-peptides-pharmacokinetic-
pharmacodynamic-and-metabolic-outcomes-volume-202-drugs-and-the-
pharmaceutical-sciences-1st-edition-randall-j-mrsny/

Real World Drug Discovery A Chemist s Guide to Biotech and

Pharmaceutical Research 1st Edition Robert M. Rydzewski

https://ebookfinal.com/download/real-world-drug-discovery-a-chemist-s-
guide-to-biotech-and-pharmaceutical-research-1st-edition-robert-m-
rydzewski/

Simulation for Designing Clinical Trials A Pharmacokinetic

Pharmacodynamic Modeling Perspective Drugs and the
Pharmaceutical Sciences Vol 127 1st Edition Hui Kimko
https://ebookfinal.com/download/simulation-for-designing-clinical-
trials-a-pharmacokinetic-pharmacodynamic-modeling-perspective-drugs-
and-the-pharmaceutical-sciences-vol-127-1st-edition-hui-kimko/
Pharmaceutical Preformulation and Formulation A
Practical Guide from Candidate Drug Selection to
Commercial Dosage Form Second Edition Drugs and the
Pharmaceutical Sciences 199 Mark Gibson Digital Instant
Download
Author(s): Mark Gibson
ISBN(s): 9781420073171, 1420073176
Edition: 2
File Details: PDF, 6.95 MB
Year: 2009
Language: english
DRUGS AND THE PHARMACEUTICAL SCIENCES VOLUME 199

SECOND EDITION

Pharmaceutical
Preformulation and
Formulation
A Practical Guide from Candidate Drug Selection to Commercial Dosage Form

edited by
Mark Gibson
 Pharmaceutical
Preformulation and
Formulation
 DRUGS AND THE PHARMACEUTICAL SCIENCES
A Series of Textbooks and Monographs

Executive Editor

James Swarbrick
PharmaceuTech, Inc.
Pinehurst, North Carolina

Advisory Board

Larry L. Augsburger Harry G. Brittain

University of Maryland Center for Pharmaceutical Physics Milford,
Baltimore, Maryland New Jersey

Jennifer B. Dressman Robert Gurny

University of Frankfurt Institute Universite de Geneve
of Pharmaceutical Technology Geneve, Switzerland
Frankfurt, Germany
Jeffrey A. Hughes
Anthony J. Hickey University of Florida College
University of North Carolina of Pharmacy
School of Pharmacy Gainesville, Florida
Chapel Hill, North Carolina
Vincent H. L. Lee
Ajaz Hussain US FDA Center for Drug
Sandoz Evaluation and Research
Princeton, New Jersey Los Angeles, California

Joseph W. Polli Kinam Park

GlaxoSmithKline Purdue University
Research Triangle Park West Lafayette, Indiana
North Carolina
Jerome P. Skelly
Stephen G. Schulman Alexandria, Virginia
University of Florida
Gainesville, Florida Elizabeth M. Topp
University of Kansas
Yuichi Sugiyama Lawrence, Kansas
University of Tokyo, Tokyo, Japan
Peter York
Geoffrey T. Tucker University of Bradford
University of Sheffield School of Pharmacy
Royal Hallamshire Hospital Bradford, United Kingdom
Sheffield, United Kingdom
 For information on volumes 1–149 in the Drugs and Pharmaceutical
Science Series, please visit www.informahealthcare.com
150. Laboratory Auditing for Quality and Regulatory Compliance, Donald Singer,
Raluca-Ioana Stefan, and Jacobus van Staden
151. Active Pharmaceutical Ingredients: Development, Manufacturing, and Regulation,
edited by Stanley Nusim
152. Preclinical Drug Development, edited by Mark C. Rogge and David R. Taft
153. Pharmaceutical Stress Testing: Predicting Drug Degradation, edited by
Steven W. Baertschi
154. Handbook of Pharmaceutical Granulation Technology: Second Edition,
edited by Dilip M. Parikh
155. Percutaneous Absorption: Drugs–Cosmetics–Mechanisms–Methodology,
Fourth Edition, edited by Robert L. Bronaugh and Howard I. Maibach
156. Pharmacogenomics: Second Edition, edited by Werner Kalow, Urs A. Meyer
and Rachel F. Tyndale
157. Pharmaceutical Process Scale-Up, Second Edition, edited by Michael Levin
158. Microencapsulation: Methods and Industrial Applications, Second Edition,
edited by Simon Benita
159. Nanoparticle Technology for Drug Delivery, edited by Ram B. Gupta and
Uday B. Kompella
160. Spectroscopy of Pharmaceutical Solids, edited by Harry G. Brittain
161. Dose Optimization in Drug Development, edited by Rajesh Krishna
162. Herbal Supplements-Drug Interactions: Scientific and Regulatory Perspectives,
edited by Y. W. Francis Lam, Shiew-Mei Huang, and Stephen D. Hall
163. Pharmaceutical Photostability and Stabilization Technology, edited by
Joseph T. Piechocki and Karl Thoma
164. Environmental Monitoring for Cleanrooms and Controlled Environments,
edited by Anne Marie Dixon
165. Pharmaceutical Product Development: In Vitro-In Vivo Correlation, edited by
Dakshina Murthy Chilukuri, Gangadhar Sunkara, and David Young
166. Nanoparticulate Drug Delivery Systems, edited by Deepak Thassu, Michel
Deleers, and Yashwant Pathak
167. Endotoxins: Pyrogens, LAL Testing and Depyrogenation, Third Edition,
edited by Kevin L. Williams
168. Good Laboratory Practice Regulations, Fourth Edition, edited by Anne
Sandy Weinberg
169. Good Manufacturing Practices for Pharmaceuticals, Sixth Edition,
edited by Joseph D. Nally
170. Oral-Lipid Based Formulations: Enhancing the Bioavailability of Poorly
Water-soluble Drugs, edited by David J. Hauss
171. Handbook of Bioequivalence Testing, edited by Sarfaraz K. Niazi
172. Advanced Drug Formulation Design to Optimize Therapeutic Outcomes,
edited by Robert O. Williams III, David R. Taft, and Jason T. McConville
173. Clean-in-Place for Biopharmaceutical Processes, edited by Dale
A. Seiberling
174. Filtration and Purification in the Biopharmaceutical Industry, Second Edition,
edited by Maik W. Jornitz and Theodore H. Meltzer
175. Protein Formulation and Delivery, Second Edition, edited by Eugene
J. McNally and Jayne E. Hastedt
176. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, Third
Edition, edited by James McGinity and Linda A. Felton
177. Dermal Absorption and Toxicity Assessment, Second Edition, edited by
Michael S. Roberts and Kenneth A. Walters
178. Preformulation Solid Dosage Form Development, edited by Moji C. Adeyeye
and Harry G. Brittain
179. Drug-Drug Interactions, Second Edition, edited by A. David Rodrigues
180. Generic Drug Product Development: Bioequivalence Issues, edited by
Isadore Kanfer and Leon Shargel
181. Pharmaceutical Pre-Approval Inspections: A Guide to Regulatory Success,
Second Edition, edited by Martin D. Hynes III
182. Pharmaceutical Project Management, Second Edition, edited by
Anthony Kennedy
183. Modified Release Drug Delivery Technology, Second Edition, Volume 1,
edited by Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts,
and Majella E. Lane
184. Modified-Release Drug Delivery Technology, Second Edition, Volume 2,
edited by Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts, and
Majella E. Lane
185. The Pharmaceutical Regulatory Process, Second Edition, edited by
Ira R. Berry and Robert P. Martin
186. Handbook of Drug Metabolism, Second Edition, edited by Paul G. Pearson and
Larry C. Wienkers
187. Preclinical Drug Development, Second Edition, edited by Mark Rogge and
David R. Taft
188. Modern Pharmaceutics, Fifth Edition, Volume 1: Basic Principles and Systems,
edited by Alexander T. Florence and Juergen Siepmann
189. Modern Pharmaceutics, Fifth Edition, Volume 2: Applications and Advances,
edited by Alexander T. Florence and Juergen Siepmann
190. New Drug Approval Process, Fifth Edition, edited by Richard A.Guarino
191. Drug Delivery Nanoparticulate Formulation and Characterization, edited by
Yashwant Pathak and Deepak Thassu
192. Polymorphism of Pharmaceutical Solids, Second Edition, edited by Harry G. Brittain
193. Oral Drug Absorption: Prediction and Assessment, Second Edition, edited by
Jennifer J. Dressman, hans Lennernas, and Christos Reppas
194. Biodrug Delivery Systems: Fundamentals, Applications, and Clinical Development,
edited by Mariko Morista and Kinam Park
195. Pharmaceutical Process Engineering, Second Edition, edited by Anthony J. Hickey
and David Ganderton
196. Handbook of Drug Screening, Second Edition, edited by Ramakrishna Seethala and
Litao Zhang
197. Pharmaceutical Powder Compaction Technology, Second Edition, edited by
Metin Celik
198. Handbook of Pharmaceutical Granulation Technology, Dilip M. Parikh
199. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate
Drug Selection to Commercial Dosage Form, Second Edition, edited by
Mark Gibson
 Pharmaceutical
Preformulation and
Formulation
Second Edition
A Practical Guide from Candidate Drug Selection to Commercial Dosage Form

edited by
Mark Gibson
AstraZeneca R&D Charnwood
Loughborough, Leicestershire, UK
Informa Healthcare USA, Inc.
52 Vanderbilt Avenue
New York, NY 10017
# 2009 by Informa Healthcare USA, Inc.
Informa Healthcare is an Informa business

No claim to original U.S. Government works

Printed in the United States of America on acid-free paper
10 9 8 7 6 5 4 3 2 1

International Standard Book Number-10: 1-4200-7317-6 (Hardcover)

International Standard Book Number-13: 978-1-4200-7317-1 (Hardcover)

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with
permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish
reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials
or for the consequence of their use.

No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or
other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information
storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://
www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923,
978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For
organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for
identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Pharmaceutical preformulation and formulation: A practical guide from candidate drug

selection to commercial dosage form / edited by Mark Gibson.
—2nd ed.
p. ; cm. — (Drugs and the pharmaceutical sciences ; 199)
Includes bibliographical references and index.
ISBN-13: 978-1-4200-7317-1 (hb : alk. paper)
ISBN-10: 1-4200-7317-6 (hb : alk. paper) 1. Drugs—Dosage forms.
I. Gibson, Mark, 1957- II. Series: Drugs and the pharmaceutical
sciences ; v. 199.
[DNLM: 1. Drug Compounding. 2. Biopharmaceutics—methods. 3.
Dosage Forms. 4. Drug Discovery. 5. Drug Evaluation. W1 DR893B v.199
2009 / QV 778 P53535 2009]
RS200.P425 2009
6150 .1—dc22
2009012458

For Corporate Sales and Reprint Permissions call 212-520-2700 or write to: Sales Department, 52 Vanderbilt Avenue,
16th floor, New York, NY 10017.

Visit the Informa Web site at

www.informa.com

and the Informa Healthcare Web site at

www.informahealthcare.com
 Preface

The first edition of this book published in 2001 has been more successful than I ever imagined,
as indicated by the excellent reviews it has received, the continued demand, and impressive
sales! I believe that the main reasons for its popularity are that there was a significant gap in
the literature and also that the information presented was based on the extensive experiences
of the various contributors who were all actively working in the industry and were willing to
share “best practice” from their knowledge and experiences. The book is intended to be a
practical guide to pharmaceutical preformulation and formulation to be used as a reference
source or a guidance tool to those working in the pharmaceutical industry or related
industries, such as biopharmaceuticals or medical devices, or anyone wanting an insight into
the subject area. Indeed, this book has also proved to be a valuable text for undergraduate and
postgraduate courses in industrial pharmacy and pharmaceutical technology. A second edition
is required because preformulation and formulation technology continues to develop and also
because there are bound to be some gaps and improvements to be filled.
The second edition still meets the main objectives of the first edition, that is, to
l provide a logical and structured approach to product development, with key stages
identified and the preformulation, biopharmaceutics, and formulation activities and
typical issues at each stage discussed, wherever possible with real or worked examples,
l emphasize what practical studies need to be undertaken for what reasons and during
what key stages of the drug development process, and
l provide separate chapters on the formulation development of each route and type of
dosage forms.
The pressure to accelerate the drug development process, shorten the development timelines,
and launch new pharmaceutical products is even more intense than before, with fewer
registrations year on year. Having a structured approach and doing the right things first time
are essential elements for achieving this. The chapters on product design and product
optimization are still very relevant but have been updated to include the quality by design
(QbD) and International Conference on Harmonisation (ICH) Q8 (product development),
ICH Q9 (quality risk management), process analytical technology (PAT), and lean
manufacturing principles that aim to link regulatory expectations to good science.
Another significant change since the first edition is the growth of biopharmaceuticals,
compared with small molecules, that deserves more attention. Pharmaceutical companies are
shifting from developing small molecules to developing biopharmaceuticals to treat a wide
range of diseases, and today approximately one in four drugs introduced to the market is a
biopharmaceutical. Since the majority of biopharmaceuticals will be delivered by injection or
infusion, the chapter on parenteral dosage forms has been updated to reflect this. Focus has
been given to the steps after purification, formulation, and subsequent fill-finish. Consider-
ation has also been given in the other chapters for handling and developing biopharmaceutical
dosage forms where there is some potential for drug delivery, for example, intranasal dosage
forms.
Elsewhere in the second edition, there are updates throughout the book to reflect on
some omissions and developments since the first edition and make it up-to-date; for example,
to reflect emerging “cutting-edge” technologies such as polymorph and salt selection and
viii Preface

prediction, molecular modeling and automation in preformulation studies, and more consider-
ation for packaging technology during development of the various dosage forms.
Once again I am indebted to all the contributors for giving up their time and energy in
producing this updated version. I am also indebted to my wife, Alison, and my family for their
support and understanding during the time I have been busy working on this book.

Mark Gibson
 Contents

Preface vii
Contributors xi

1. Introduction and Perspective 1

Mark Gibson

2. Aiding Candidate Drug Selection: Introduction and Objectives 11

Mark Gibson

3. Preformulation Investigations using Small Amounts of Compound as an Aid to

Candidate Drug Selection and Early Development 17
Gerry Steele and Talbir Austin

4. Biopharmaceutical Support in Candidate Drug Selection 129

Anna-Lena Ungell and Bertil Abrahamsson

5. Early Drug Development: Product Design 172

Mark Gibson

6. Preformulation as an Aid to Product Design in Early Drug Development 188

Gerry Steele

7. Biopharmaceutical Support in Formulation Development 247

Bertil Abrahamsson and Anna-Lena Ungell

8. Product Optimization 289

Mark Gibson

9. Parenteral Dosage Forms 325

Joanne Broadhead and Mark Gibson

10. Inhalation Dosage Forms 348

Paul Wright

11. Oral Solid Dosage Forms 367

Peter Davies

12. Ophthalmic Dosage Forms 431

Mark Gibson
x Contents

13. Aqueous Nasal Dosage Forms 456

Nigel Day

14. Topical and Transdermal Delivery 475

Kenneth A. Walters and Keith R. Brain

Index 527
 Contributors

Bertil Abrahamsson AstraZeneca, Mölndal, Sweden

Talbir Austin AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

Keith R. Brain Cardiff University, Cardiff, U.K.

Joanne Broadhead AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

Peter Davies Shire Pharmaceutical Development Ltd., Basingstoke, U.K.

Nigel Day AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

Mark Gibson AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

Gerry Steele AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

Anna-Lena Ungell AstraZeneca, Mölndal, Sweden

Kenneth A. Walters An-eX Analytical Services Ltd., Cardiff, U.K.

Paul Wright AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

 1 Introduction and Perspective
Mark Gibson
AstraZeneca R&D Charnwood, Loughborough, Leicestershire, U.K.

INTRODUCTION

This book is intended to be a practical guide to pharmaceutical preformulation and formulation.

It can be used as a reference source and a guidance tool for those working in the pharmaceutical
industry or related industries, for example, medical devices and biopharmaceuticals, or anyone
wanting an insight into this subject area. The information presented is essentially based on the
extensive experiences of the editor and various other contributors who are all actively working in
the industry and have learned “best practice” from their experiences.
There are various excellent books already available that cover the theoretical aspects of
different types of pharmaceutical dosage forms and processes. A variety of books are also available
that focus on the drug development process, business, and regulatory and project management
aspects. The popularity of the first edition of this book, Pharmaceutical Preformulation and Formulation:
A Practical Guide from Candidate Drug Selection to Commercial Formulation, confirms my opinion that
there is a need for a pragmatic guide to pharmaceutical preformulation and formulation with an
emphasis on what practical studies need to be undertaken, for what reasons, and during what key
stages of the drug development process. Preformulation, biopharmaceutics, and formulation are all
important for candidate drug selection and through the various stages of product development as
shown in Figure 3. This book has been written to try and address this need.
A logical approach to product development is described in the book, with the key stages
identified and the preformulation, biopharmaceuticals, and formulation activities and typical
issues at each stage discussed. Wherever possible, the book is illustrated with real or worked
examples from contributors who have considerable relevant experience of preformulation,
biopharmaceuticals, and formulation development.
Jim Wells’ book on preformulation (Wells, 1988) made a strong impact on trainees and
pharmaceutical scientists (including myself) working in this field of the pharmaceutical
industry when it was introduced two years ago. It describes the important concepts and
methods used in preformulation with the underlying theory. To his credit, Wells’ book is still
useful today, but sadly, the book is now out of print, and existing copies are hard to obtain. It
also requires updating to include the abundance of modern preformulation instrumental
techniques that have emerged, such as thermogravimetric analysis (TGA), hot-stage micros-
copy (HSM), X-ray powder diffraction (XRPD), Raman and infrared spectroscopy, and solid-
state nuclear magnetic resonance (NMR). These techniques can be used to provide valuable
information to characterize the drug substance and aid formulation development using the
minimal amounts of compound.
Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug
Selection to Commercial Formulation covers a wider subject area than just preformulation. Topics
include biopharmaceutics, drug delivery, formulation, and process development aspects of
product development. The book also describes a logical and structured approach to the
product development process, recommending at what stages appropriate preformulation,
biopharmaceutics, and formulation work are best undertaken.

DRUG DEVELOPMENT DRIVERS, CHALLENGES, RISKS, AND REWARDS

It is important that the reader is aware of the nature of pharmaceutical research and
development (R&D) to appreciate the importance of preformulation and formulation in the
overall process.
2 Gibson

Table 1 Major Hurdles to Successful Product Registration and Sale

Activity Requirements

Research Novel compound (Is it patentable?)

Novel biological mechanism (Is it patentable?)
Unmet medical needs
Potent and selective
Safety High margin of safety
Nontoxic (not carcinogenic, tetratogenic, mutagenic, etc.)
Clinical Tolerable side effects profile
Efficacious
Acceptable duration of action
Drug process Bulk drug can be synthesized/scaled up
Pharmaceutical Acceptable formulation/pack (meets customer needs)
Drug delivery/product performance acceptable
Stable/acceptable shelf life
Robust clinical trial process, which can be scaled up and transferred into operations
Regulatory Quality of data/documentation
Manufacturing Manufacturable
Acceptable cost of goods
Able to pass preapproval inspection
Marketing/commercial Competitive
Meets customer needs
Value for money
Commercial return

In simple terms, the objective of pharmaceutical R&D can be defined as “converting ideas into
candidate drugs for development” and the objective of product development as “converting candidate
drugs into products for registration and sale.” In reality, these goals are extremely challenging and
difficult to achieve because of the many significant hurdles a pharmaceutical company has to
overcome during the course of drug development. Some of the major hurdles are listed in Table 1.
The high risk of failure in drug discovery and development throughout the pharma-
ceutical industry statistically shows that, on average, only 1 in 5000 compounds screened in
research will reach the market. For those that are nominated for development, the failure rate
will vary from one in five to one in ten compounds that will achieve registration and reach the
marketplace. Most failures in early development are due to drug toxicity or safety issues,
whereas a lack of efficacy is the primary reason for late-stage attrition (Lowe, 2008). The
relatively high attrition rates of new medicines is a major challenge, particularly when they are
expensive phase III clinical failures that have occurred in recent years. Regulators are being
more selective in what they approve, and they are demanding more data on efficacy and side
effects. Only about 20 new drugs are now approved every year, down from 40 or 50 a decade
ago and despite an approximate 70% increase in R&D investment over the last 10 years. On top
of this, there is a significant commercial risk from those that are marketed; only 3 out of 10 are
likely to achieve a fair return on investment. The products that give poor return on investment
are often the result of poor candidate drug selection (the compound does not have the desired
properties of safety, selectivity, efficacy, potency, or duration) and/or poor product
development (the development program does not establish the value of the product). The
latter scenario should, and can be, avoided by careful assessment at the “product design” stage
of development. Product design is discussed further in chapter 5.
There has been a recent worrying trend of marketed products being withdrawn a few
years after launch. This may be because once it is used by many thousands, or even millions, of
people, rare but significant side effects can emerge. For example, Merck’s blockbuster arthritis
drug, Vioxx, was approved in 1999 but withdrawn five years later when linked to increased
cardiovascular risks. Another example is the surprise announcement by Pfizer when it
withdrew the world’s first inhalable insulin product, Exubera, from the market in 2007
following disappointing sales. It would seem that the company had failed to appreciate the
customer requirements well enough during the product design phase of development.
Introduction and Perspective 3

Figure 1 Product life cycle.

To be successful and competitive, research-based pharmaceutical companies must

ensure that new discoveries are frequently brought to the market to generate cash flow. This is
required to fund the next generation of compounds to meet the therapeutic needs of patients,
and of course, to benefit the shareholders. This cycle of events is sometimes referred to as the
“product life cycle” and is further illustrated in Figure 1.
The overall costs of drug discovery and development to bring a new medicine to the
market are increasing at an alarming rate. It is currently estimated that US$1 billion is required
to recoup the costs of research, development, manufacturing, distribution, marketing, and
sales for a new chemical entity (NCE). Cost estimates are even higher for a new
biopharmaceutical product at US$1.2 billion and take longer to develop than a NCE, but
tend to enjoy much greater success rates (DiMari and Grabowski, 2007). A significant
proportion of this total is for the cost of failures, or in other words, the elimination of
unsuccessful compounds. R&D expenditure tends to increase substantially as the compound
progresses from drug discovery research through the various clinical trial phases of
development. The pivotal phase III patient trials are usually the largest, involving thousands
of patients, and hence the most expensive. To reduce development costs, some companies
selectively screen and eliminate compounds earlier in the drug development process on the
basis of results from small-scale, less expensive studies in human and progress fewer, more
certain compounds to later clinical phases.
In spite of the high risks and high costs involved, there is still a huge incentive for
pharmaceutical companies to seek the financial rewards from successful marketed products,
especially from the phenomenal success of the rare “blockbuster” (reaching sales of >US$1 billion
per year). This can earn the company significant profits to reinvest in research and fund the
product development pipeline.
Another factor, the risk of delay to registration and launch, can also have a significant
impact on the financial success of a marketed product. McKinsey & Company, a management
consultancy, assessed that a product that is six months late to market will miss out on one-
third of the potential profit over the product’s lifetime. In comparison, they found that a
development cost overspend of 50% would reduce profits by just 3.5%, and a 9% overspend in
production costs would reduce profits by 22% (McKinsey & Co., 1991). The loss of product
Other documents randomly have
different content
 Microbiology - Study Plan
First 2023 - Division

Prepared by: Professor Johnson

Date: August 12, 2025

Background 1: Interdisciplinary approaches

Learning Objective 1: Historical development and evolution
• Practical applications and examples
- Sub-point: Additional details and explanations
- Example: Practical application scenario
Learning Objective 2: Theoretical framework and methodology
• Problem-solving strategies and techniques
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Learning Objective 3: Research findings and conclusions
• Assessment criteria and rubrics
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Learning Objective 4: Research findings and conclusions
• Comparative analysis and synthesis
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Learning Objective 5: Learning outcomes and objectives
• Practical applications and examples
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 5: Diagram/Chart/Graph]
Practice Problem 5: Problem-solving strategies and techniques
• Key terms and definitions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Important: Key terms and definitions
• Research findings and conclusions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
Example 7: Statistical analysis and interpretation
• Key terms and definitions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Key Concept: Practical applications and examples
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Definition: Practical applications and examples
• Research findings and conclusions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Conclusion 2: Comparative analysis and synthesis
Example 10: Current trends and future directions
• Statistical analysis and interpretation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
[Figure 11: Diagram/Chart/Graph]
Remember: Best practices and recommendations
• Key terms and definitions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
[Figure 12: Diagram/Chart/Graph]
Definition: Best practices and recommendations
• Historical development and evolution
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Practice Problem 13: Research findings and conclusions
• Study tips and learning strategies
- Sub-point: Additional details and explanations
- Example: Practical application scenario
Example 14: Assessment criteria and rubrics
• Best practices and recommendations
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 15: Diagram/Chart/Graph]
Example 15: Theoretical framework and methodology
• Key terms and definitions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Example 16: Historical development and evolution
• Theoretical framework and methodology
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 17: Diagram/Chart/Graph]
Definition: Interdisciplinary approaches
• Assessment criteria and rubrics
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Theoretical framework and methodology
• Best practices and recommendations
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Example 19: Study tips and learning strategies
• Best practices and recommendations
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Practice 3: Study tips and learning strategies
Example 20: Fundamental concepts and principles
• Statistical analysis and interpretation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Definition: Critical analysis and evaluation
• Literature review and discussion
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
[Figure 22: Diagram/Chart/Graph]
Key Concept: Experimental procedures and results
• Literature review and discussion
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Fundamental concepts and principles
• Critical analysis and evaluation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Key terms and definitions
• Fundamental concepts and principles
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 25: Diagram/Chart/Graph]
Note: Study tips and learning strategies
• Best practices and recommendations
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Definition: Historical development and evolution
• Statistical analysis and interpretation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 27: Diagram/Chart/Graph]
Note: Critical analysis and evaluation
• Theoretical framework and methodology
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Important: Fundamental concepts and principles
• Fundamental concepts and principles
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 29: Diagram/Chart/Graph]
Key Concept: Learning outcomes and objectives
• Critical analysis and evaluation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Summary 4: Fundamental concepts and principles
Definition: Best practices and recommendations
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
[Figure 31: Diagram/Chart/Graph]
Example 31: Study tips and learning strategies
• Fundamental concepts and principles
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Example 32: Research findings and conclusions
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Remember: Theoretical framework and methodology
• Comparative analysis and synthesis
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Comparative analysis and synthesis
• Current trends and future directions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 35: Diagram/Chart/Graph]
Example 35: Case studies and real-world applications
• Assessment criteria and rubrics
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Key Concept: Interdisciplinary approaches
• Literature review and discussion
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Note: Theoretical framework and methodology
• Literature review and discussion
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Note: Best practices and recommendations
• Learning outcomes and objectives
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Important: Key terms and definitions
• Fundamental concepts and principles
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Test 5: Learning outcomes and objectives
Important: Assessment criteria and rubrics
• Historical development and evolution
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Example 41: Historical development and evolution
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Practice Problem 42: Key terms and definitions
• Practical applications and examples
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Practice Problem 43: Best practices and recommendations
• Statistical analysis and interpretation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Key Concept: Statistical analysis and interpretation
• Experimental procedures and results
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 45: Diagram/Chart/Graph]
Example 45: Experimental procedures and results
• Theoretical framework and methodology
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Example 46: Interdisciplinary approaches
• Experimental procedures and results
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Note: Study tips and learning strategies
• Literature review and discussion
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Case studies and real-world applications
• Study tips and learning strategies
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Important: Ethical considerations and implications
• Learning outcomes and objectives
- Sub-point: Additional details and explanations
- Example: Practical application scenario
Formula: [Mathematical expression or equation]
Practice 6: Critical analysis and evaluation
Important: Research findings and conclusions
• Case studies and real-world applications
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Important: Ethical considerations and implications
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
[Figure 52: Diagram/Chart/Graph]
Key Concept: Interdisciplinary approaches
• Interdisciplinary approaches
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Important: Critical analysis and evaluation
• Key terms and definitions
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Formula: [Mathematical expression or equation]
Key Concept: Historical development and evolution
• Statistical analysis and interpretation
- Sub-point: Additional details and explanations
- Example: Practical application scenario
- Note: Important consideration
Welcome to our website – the ideal destination for book lovers and
knowledge seekers. With a mission to inspire endlessly, we offer a
vast collection of books, ranging from classic literary works to
specialized publications, self-development books, and children's
literature. Each book is a new journey of discovery, expanding
knowledge and enriching the soul of the reade

Our website is not just a platform for buying books, but a bridge
connecting readers to the timeless values of culture and wisdom. With
an elegant, user-friendly interface and an intelligent search system,
we are committed to providing a quick and convenient shopping
experience. Additionally, our special promotions and home delivery
services ensure that you save time and fully enjoy the joy of reading.

Let us accompany you on the journey of exploring knowledge and

personal growth!

ebookfinal.com